C12N2501/724

SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

METHODS FOR SELECTIVE INHIBITION OF PLURIPOTENT STEM CELLS
20190300847 · 2019-10-03 ·

Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.

Augmentation of cell therapy efficacy including treatment with alpha 1,3 fucosyltransferase

Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.

Viral resistant cells and uses thereof

The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.

Hematopoietic progenitor cell populations having affinity for E-selectin / L-selectin
10370642 · 2019-08-06 · ·

The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.

SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

METHOD FOR PREPARING CORNEAL TISSUE
20190231929 · 2019-08-01 ·

A method for preparing corneal tissue for applications predominantly in transplantation, and to the use of a solution for decellularizing corneal tissue. Methods of transplanting corneal tissue.

PRODUCTION OF N-GLYCOPROTEINS FOR ENZYME ASSISTED GLYCOMODIFICATION

The present invention relates to a cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in improvement of pharmacokinetic properties, i.e. by attaching PEG chains to proteins. The present invention also relates to methods for producing the antibodies and compositions comprising the antibodies, and their uses.

GLYCOENGINEERING OF E-SELECTIN LIGANDS
20190201444 · 2019-07-04 ·

The present invention provides methods of enforcing expression of an E-selectin and/or L-selectin ligand on a surface of a cell. Also provided are methods of enabling and/or increasing binding of a cell to E-selectin and/or L-selectin, methods of increasing homing and/or extravasation in a population of transplanted cells, methods of producing modified cells, including stem cells, for transplanting into a subject, methods of treating or ameliorating the effects of a symptom, a disease or an injury in a subject, and methods for inducing and/or enhancing homing of a population of cells to a therapeutic target in a subject. The invention further provides pharmaceutical compositions comprising a population of cells produced by the methods of the invention and kits that include such compositions for treating or ameliorating the effects of a symptom, a disease or an injury in a subject.

Labeling hydroxymethylated residues

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.